Biogen Inc

NASDAQ:BIIBUnited States

01:12 PM EST, 11/29/2024 (MT Newswires) -- Biogen (BIIB) and Eisai have launched Leqembi, an anti-amyloid antibody treatment for early Alzheimer's disease, in South Korea following regulatory approval in May, Biogen said late Wednesday. Eisai Korea ...

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's drug candidates, including lecanemab; actual timing and content of submissions to and decisions made by the regulatory authorities regarding lecanemab; uncertainty of success in the development and potential commercialization of lecanemab; failure to protect and enforce Biogen's data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks, results of operations and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements.

Ratings actions from Benzinga: https://www.benzinga.com/quote/BIIB/analyst-ratings

(END) Dow Jones Newswires

November 21, 2024 08:18 ET (13:18 GMT)